JP2025508963A - ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体及びその使用方法 - Google Patents

ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体及びその使用方法 Download PDF

Info

Publication number
JP2025508963A
JP2025508963A JP2024552169A JP2024552169A JP2025508963A JP 2025508963 A JP2025508963 A JP 2025508963A JP 2024552169 A JP2024552169 A JP 2024552169A JP 2024552169 A JP2024552169 A JP 2024552169A JP 2025508963 A JP2025508963 A JP 2025508963A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
ceacam1
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552169A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023168326A5 (https=
JP2025508963A5 (https=
Inventor
エス．ブラムバーグ リチャード
ファン ユ－ファ
ガンディー アミット
ジョージ エドワード ホルゲート ロバート
ロバート ハーン アロン
ダナ ジョーンズ スーザン
Original Assignee
ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド filed Critical ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド
Publication of JP2025508963A publication Critical patent/JP2025508963A/ja
Publication of JPWO2023168326A5 publication Critical patent/JPWO2023168326A5/ja
Publication of JP2025508963A5 publication Critical patent/JP2025508963A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024552169A 2022-03-03 2023-03-02 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体及びその使用方法 Pending JP2025508963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316140P 2022-03-03 2022-03-03
US63/316,140 2022-03-03
PCT/US2023/063559 WO2023168326A2 (en) 2022-03-03 2023-03-02 Humanized and affinity-matured anti-ceacam1 antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2025508963A true JP2025508963A (ja) 2025-04-10
JPWO2023168326A5 JPWO2023168326A5 (https=) 2026-03-09
JP2025508963A5 JP2025508963A5 (https=) 2026-03-09

Family

ID=87884376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552169A Pending JP2025508963A (ja) 2022-03-03 2023-03-02 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体及びその使用方法

Country Status (7)

Country Link
US (1) US20250388666A1 (https=)
EP (1) EP4486380A2 (https=)
JP (1) JP2025508963A (https=)
CN (1) CN119032103A (https=)
AU (1) AU2023227877A1 (https=)
CA (1) CA3245215A1 (https=)
WO (1) WO2023168326A2 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2785743B1 (en) * 2011-12-01 2019-08-14 The Brigham and Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
WO2015101996A1 (en) * 2014-01-02 2015-07-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells

Also Published As

Publication number Publication date
AU2023227877A1 (en) 2024-09-19
WO2023168326A2 (en) 2023-09-07
EP4486380A2 (en) 2025-01-08
CA3245215A1 (en) 2023-09-07
US20250388666A1 (en) 2025-12-25
CN119032103A (zh) 2024-11-26
WO2023168326A3 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
KR102472087B1 (ko) 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
KR102629403B1 (ko) Vista 항원 결합 분자
EP4286410A1 (en) Single-domain antibody against cd16a and use thereof
BR112021009325A2 (pt) Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
US20250074980A1 (en) Humanized and Affinity-Matured Anti-CEACAM1 Antibodies
TW201920282A (zh) 抗egfr和pd-1的雙特異性抗體
JP7843824B2 (ja) 抗体および使用方法
KR20210121102A (ko) 항-cd79b 항체, 이의 항원-결합 단편, 및 이의 약학적 용도
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
JP2025525916A (ja) 抗ｃｃｒ８抗体及び使用方法
EP3524624A1 (en) Anti-cd27 antibody, antigen-binding fragment thereof, and medical use of same
US20250388666A1 (en) Humanized and affinity-matured anti-ceacam1 antibodies and methods of use
US20250326849A1 (en) COMBINATION OF A FcyRIIB- AND A TUMOR ANTIBODY FOR USE IN THE TREATMENT OF AN FcyRIIB-NEGATIVE CANCER
KR102956480B1 (ko) 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
WO2025104253A1 (en) Anti-muc16 antibodies and uses thereof
KR20250021299A (ko) Lypd3에 대한 항체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260227